Table 3a.
Frontal lobe phospholipid mass in SSADH deficient patient and control group
| nmol/g ww | mol % | |||||
|---|---|---|---|---|---|---|
|
|
||||||
| Patient | Mean (control) | SD | Patient | Mean (control) | SD | |
|
|
||||||
| EtnGpl | 12519 | 16153 | 2886 | 38.2% | 39% | 1.6% |
| PtdIns | 1549 | 1840 | 243 | 4.7% | 4.5% | 0.6% |
| PtdSer | 1792 | 4818 | 1390* | 5.5% | 11.5% | 2.1%* |
| ChoGpl | 14339 | 14474 | 2338 | 43.7% | 35.2% | 3.9%* |
| CerPCho | 2614 | 4036 | 1032 | 8.0% | 9.7% | 1.7% |
| Total | 32812 | 41321 | 6911 | |||
| n = 1 | n = 4 | |||||
Mass values are expressed as nmol phosphorus/gram wet weight tissue and represent mean±SD of control and patient values. Molar composition values are expressed as mol % of total phosphorus. n = 2–4.
*
indicates significance between patient and control group, 2 SD from control mean.